{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-26-000004","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.908883+00:00","generated_at":"2026-05-16T00:44:55.843951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M","bullets":["Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).","Growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) combined revenue $161.3M in Q4 (+45% YoY).","ONAPGO net sales $8.9M since launch; new patient initiation resumed Q1 2026; second supplier expected 2027.","Cash and marketable securities $308.7M at Dec 31, 2025.","FY 2026 guidance: revenue $840-870M, operating earnings $0-30M, adjusted operating earnings $140-170M."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-26-000004","json":"https://secwatch.observer/filing/0001356576-26-000004.json","markdown":"https://secwatch.observer/filing/0001356576-26-000004.md","text":"https://secwatch.observer/filing/0001356576-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000004/0001356576-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000004/supn-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:44:55.843951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}